Dr. Terrence Cescon
Claim this profileReading Hospital
Expert in Cancer
Expert in Adenocarcinoma
61 reported clinical trials
114 drugs studied
About Terrence Cescon
Education:
- Obtained MD from Drexel University College of Medicine in 2015.
- Completed Residency in Internal Medicine at Reading Hospital, serving as Chief Resident (2018-2019).
- Finished Fellowship in Hematology/Oncology at Fox Chase Cancer Center in 2022.
Experience:
- Specializes in Hematology/Oncology with comprehensive training and experience based in Pennsylvania, United States.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Adenocarcinoma
Global LeaderStage IV
Stage III
HER2 negative
Affiliated Hospitals
Clinical Trials Terrence Cescon is currently running
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
More about Terrence Cescon
Clinical Trial Related1 year of experience running clinical trials · Led 61 trials as a Principal Investigator · 32 Active Clinical TrialsTreatments Terrence Cescon has experience with
- Paclitaxel
- Nivolumab
- Fluorouracil
- Carboplatin
- Cisplatin
- Atezolizumab
Breakdown of trials Terrence Cescon has run
Cancer
Adenocarcinoma
Breast Cancer
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Terrence Cescon specialize in?
Terrence Cescon focuses on Cancer and Adenocarcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Terrence Cescon currently recruiting for clinical trials?
Yes, Terrence Cescon is currently recruiting for 28 clinical trials in West Reading Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Terrence Cescon has studied deeply?
Yes, Terrence Cescon has studied treatments such as Paclitaxel, Nivolumab, Fluorouracil.
What is the best way to schedule an appointment with Terrence Cescon?
Apply for one of the trials that Terrence Cescon is conducting.
What is the office address of Terrence Cescon?
The office of Terrence Cescon is located at: Reading Hospital, West Reading, Pennsylvania 19611 United States. This is the address for their practice at the Reading Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.